FilingSEC EDGAR8-K
Telomir Pharmaceuticals Reports Anti-Cancer Activity of Telomir-Zn in Osteosarcoma Models
· SEC accepted
StagePreclinical
Filing content
Telomir Pharmaceuticals announced research findings from The Ohio State University demonstrating that Telomir-Zn inhibits cell growth in human and canine osteosarcoma models.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…